Short answer
Tango Therapeutics, Inc. (TNGX) filed its Q1 2026 10-Q quarterly report on May 13, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $0 (down 100.0% year over year) with net income of −$46M.
Q1 2026 key financials · XBRL
- Revenue
- $0
- −100.0% YoY
- Net income
- −$46M
- −14.1% YoY
- EPS (diluted)
- −$0.32
- +11.1% YoY
Source: XBRL data from the Tango Therapeutics, Inc. (TNGX) Q1 2026 10-Q on SEC EDGAR. USD.
Tango Therapeutics, Inc. Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- No material risk-factor changes from the December 31, 2025 Form 10-K
- Carried-forward risks could materially affect business, financial condition, and operating results
- Additional unknown or currently immaterial risks may materially adversely affect results
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Tango Therapeutics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.